Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Rare Diseases

Exploring the Market Potential of the Upcoming ...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It occurs when the communication between nerve cells and muscles is disrupted. This impairment prevents critical ...

Oct 01, 2021

pharma-biotech-news-updates-for-biogen-smartlabs-synlogic-partner-therapeutics
Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain

Win-win for Biogen as its Biosimilar Gets Approval for AMD  Samsung Bioepis and Biogen's biosimilar drug, Byooviz, received USFDA approval for the treatment of vision loss, Age-related macular degeneration and has become the first biosimilar to Lucentis in the AMD market. The Lucentis copycat had also manag...

Find More
recent-pharma-news-updates-for-adarx-ixaka-novocure-vor-biopharma
ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System

ADARx bags USD 75 Million to advance its RNA tech pipeline ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics, announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. SR One Capital Management and OrbiMed Advisors co-led Series ...

Find More
phenylketonuria-market
Which Pipeline Therapy is Expected to Capture the Eyeballs in the Phenylketonuria Market?

Phenylketonuria is an inherited disorder characterized by the absence or deficiency of an enzyme called phenylalanine hydroxylase (PAH), responsible for processing the amino acid phenylalanine. The condition affects one in 13,500 to 19,000 newborns in the United States, says NORD. DelveInsight’s Phenylketonuria epi...

Find More

More Views & Analysis

pharma-happenings-for-roche-allstripes-datavant-bluewillow-shape-therapeutics
Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 Billion Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technol...

Find More

pharma-happenings-for-merck-abbvie-incyte-aprea-eisai
Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea’s Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer

FDA Approves Keytruda in Both Adjuvant and Neoadjuvant Setting in High-Risk Early-Stage TNBC In July 2021, the US FDA approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as...

Find More

primary-hyperoxaluria-market-cagr-size-share-trends-growth-and-key-companies
Primary Hyperoxaluria Market Size Observes Growth with a Substantial CAGR

Primary hyperoxaluria (PH) is a rare autosomal genetic form of Hyperoxaluria, a condition that leads to the excessive urinary excretion of oxalate. Till now, three distinct hereditary enzymatic deficiencies have been identified as a cause of PH, namely, PH type 1 (PH1), type 2 (PH2), and type 3 (PH3), with PH1 as t...

Find More

Angelman syndrome
Angelman syndrome Pipeline: Unmet needs call for a robust pipeline

The necessity of a robust Angelman syndrome pipeline is indispensable at the current moment because of a shortage of any approved therapy option available in the market. The Angelman Syndrome current treatment landscape consists of symptomatic therapy options worth USD 330.2 million in 2017.  Treatment entire...

Find More

adult-onset-stills-disease-treatment-market
Essential Demands Impinge the Evolving Adult-onset Still’s Disease Treatment Market

Adult-onset Still’s Disease (AoSD), alternatively known as systemic-onset juvenile idiopathic arthritis, is a rare systemic inflammatory disorder of unknown etiology. There are three main patterns of AoSD’s clinical course: monophasic, intermittent, and chronic.  Although there is an approximately equal distri...

Find More

recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos
InnoCare’s Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab

InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today announced the approval of Phase I clinical trial of its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, by the China...

Find More

Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are cha.....

Find More

Though appear rare, rare diseases are far from being rare. With over 7,000 rare disease affecting mi.....

Find More

Peanut Allergy accounts for the majority of severe food-associated allergic reactions. It is strictl.....

Find More

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....

Find More

Virtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with t.....

Find More

Fibrodysplasia Ossificans Progressiva (FOP) is a rare disorder that results in gradual ossification .....

Find More